K-V Pharmaceutical Company Receives Notification From New York Stock Exchange Of Compliance With Quantitative Continued Listing Standards
September 2, 2010 - September 2, 2010, St. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has received notification from the New York Stock Exchange (“NYSE”) stating that the Company has reestablished compliance with the NYSE’s minimum share price requirements for continued listing on an accelerated basis.

K-V Pharmaceutical Company Announces the Election of New Independent Member to Board of Directors
August 9, 2010 - August 9, 2010, 5t. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that Mr. Robert Baldini was appointed as a new independent member of the Board of Directors by a unanimous vote of the directors, which also voted to increase the size of the Board to eight directors.

K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance with Continued Listing Standards
August 2, 2010 - August 2, 2010, St. Louis, MO., - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that the Company received notification from the New York Stock Exchange (UNYSEU) on July 27, 2010 of non-compliance regarding the Company's quantitative continued listing standards. The NYSE informed the Company that its Class A Common Stock equity issue has fallen below criteria for the average closing price of a NYSE security of not less than $1.00 over a consecutive 30-trading day period . This notification pertains to the Class A Common Stock but also affects the Class B Common Stock. The NYSE advised the Company that it is required to bring the Class A share price and average share price back above $1.00 within six months of receiving the notification of non-compliance in order to avoid the commencement of suspension and delisting procedures for its common shares. The Company could cure the noncompliance sooner than the end of the six-month period if the trading price of its Class A Common Stock is at least $1.00 per share on the last trading day of a calendar month within the six-month period and the average share price over the 30-trading days preceding the end of that month is at least $1.00 per share. The NYSE advised the Company that the first such month-end assessment will take place beginning July 31, 2010. The Class A Common Stock has recently begun to trade at levels above $1.00, with a closing price of $1.07 on July 30, 2010. The 30-day average of the Class A Common Stock on the last trading day of July did not, however, meet the NYSE 30-day average requirement of trading above $1.00 as of that date.

ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets
December 23, 2008

KV Pharmaceutical Voluntarily Suspends All Shipments of its Approved Tablet-form Drugs
December 23, 2008

For additional press releases, go to the press release archive.